>
Switch to:

Illumina Long-Term Capital Lease Obligation

: $803 Mil (As of Mar. 2022)
View and export this data going back to 2000. Start your Free Trial

Illumina's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2022 was $803 Mil.

Illumina's quarterly Long-Term Capital Lease Obligation declined from Sep. 2021 ($784 Mil) to Dec. 2021 ($774 Mil) but then increased from Dec. 2021 ($774 Mil) to Mar. 2022 ($803 Mil).

Illumina's annual Long-Term Capital Lease Obligation declined from Dec. 2019 ($695 Mil) to Dec. 2020 ($671 Mil) but then increased from Dec. 2020 ($671 Mil) to Dec. 2021 ($774 Mil).

Illumina Long-Term Capital Lease Obligation Historical Data

The historical data trend for Illumina's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Long-Term Capital Lease Obligation
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 695.00 671.00 774.00

Illumina Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Long-Term Capital Lease Obligation Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 664.00 704.00 784.00 774.00 803.00

Illumina  (NAS:ILMN) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Illumina Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Illumina's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Illumina Business Description

Illumina logo
Industry
Healthcare » Medical Diagnostics & Research NAICS : 621511 SIC : 8071
Comparable Companies
XSWX:LONN SHSE:603259 NYSE:IQV NAS:IDXX NYSE:A NYSE:MTD NYSE:LH NYSE:PKI XPAR:ERF NAS:ICLR
Traded in Other Exchanges
ILMN:Mexico 0J8Z:UK ILU:Germany ILU:Germany ILU:Germany I1LM34:Brazil ILMN:Austria
Address
5200 Illumina Way, San Diego, CA, USA, 92122
Website
https://www.illumina.com
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
Executives
Flatley Jay T director 9885 TOWNE CENTRE DR SAN DIEGO CA 92121
Tousi Susan H officer: SVP Product Development 5200 ILLUMINA WAY SAN DIEGO CA 92122
Reeves Kathryne Gambrell officer: SVP, Chief Marketing Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Goswami Joydeep officer: SVP Corp Business Development SUMITOMO FUDOSAN MITA TWIN BLDG EAST WING 4-2-8 SHIBAURA MINATO-KU TOKYO M0 1080023
Dadswell Charles officer: SVP & General Counsel 5200 ILLUMINA WAY SAN DIEGO CA 92122
Desouza Francis A director, officer: President and CEO 350 ELLIS STREET MOUNTAIN VIEW CA 94043
Van Oene Mark officer: SVP Chief Commercial Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Ragusa Robert P officer: SVP, Global Quality & Ops PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: RAGUSA ROBERT P a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Mcginnis Karen K officer: VP, Chief Accounting Officer INSIGHT ENTERPRISES INC 1305 WEST AUTO DRIVE TEMPE AZ 85284
Hoyt Aimee L officer: SVP, Chief People Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Ronaghi Mostafa officer: SVP, Entrepreneurial Devlopmt 9885 TOWNE CENTRE DRIVE SAN DIEGO CA 92121
Aravanis Alexander officer: SVP, Chief Technology Officer 5200 ILLUMINA WAY SAN DIEGO CA 92122
Siegel Susan E director 3000 SAND HILL ROAD BLDG 3 STE 290 MENLO PARK CA 94025
Thompson John Wendell director C/O MICROSOFT CORPORATION ONE MICROSOFT WAY REDMOND WA 98053
Epstein Robert S director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: EPSTEIN ROBERT S a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}

Illumina Headlines

From GuruFocus

GRAIL and Premier's PINC AI™ Partner to Support Patient Access to Galleri® Multi-Cancer Early Detection Blood Test

By Business Wire 01-10-2022

Illumina Unveils Groundbreaking Comprehensive Genomic Profiling Test for Cancer in Europe

By PRNewswire 03-15-2022

Illumina partners with centers across France to advance a precision medicine approach for patients with late-stage cancer

By PRNewswire 02-03-2022

Illumina collaborates with Nashville Biosciences to accelerate medicines development

By PRNewswire 01-10-2022

Illumina and Syapse Partner on Research to Evaluate Large Panel Biomarker Testing Patterns Across US Community Oncology Practices

By GuruFocusNews 01-04-2022

Illumina and Sequoia Capital China Select First Startups to join Genomics Incubator in China

By PRNewswire 11-17-2021

GRAIL Announces Partnership with Alignment Health Plan as First Medicare Advantage Plan to Offer Galleri® Multi-Cancer Early Detection Blood Test

By Business Wire 12-06-2021

GRAIL and Point32Health Collaborate to Offer Galleri® Multi-Cancer Early Detection Blood Test

By PRNewswire 02-15-2022

Telos Capital Management, Inc. Buys Illumina Inc, United Parcel Service Inc, Newell Brands Inc, Sells Activision Blizzard Inc, iShares Biotechnology ETF, Merck Inc

By insider 01-21-2022

Illumina Partners with Agendia to Expand Genomic Testing in Breast Cancer Care

By PRNewswire 01-10-2022

Other Sources

Illumina's (ILMN) GRAIL, Point32Health Unite to Offer MCED Test

By Zacks 2022-02-16

Illumina (ILMN) Ties Up With Syapse to Evaluate Biomarker Testing

By Zacks 2022-01-05

OTR Global Upgrades Illumina (ILMN) to Buy

By tipranks.com 2022-03-30

Illumina (ILMN) Q4 Earnings Top Estimates, Gross Margin Up

By Zacks 2022-02-11

$ILMN - Illumina, Inc. (ILMN) JPMorgan 40th Annual Healthcare Conference (Transcript). Illumina Inc Ilmn Jpmorgan 40th Annual Healthcare Conference Transcript

By Seekingalpha 2022-01-10

Company News for Jan 12, 2022

By Zacks 2022-01-12

Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

By Zacks 2022-02-03

Top Research Reports for Merck, Shopify & Intercontinental Exchange

By Zacks 2022-02-18

Illumina (ILMN) to Develop Synthetic Genomic Data With New Pact

By Zacks 2021-12-15

Why Illumina (ILMN) is Poised to Beat Earnings Estimates Again

By Zacks 2022-01-13

4 Toxic Stocks to Eliminate From Your Portfolio Now

By Zacks 2021-12-27

Illumina (ILMN) Q4 Earnings and Revenues Beat Estimates

By Zacks 2022-02-10

Is a Surprise Coming for Illumina (ILMN) This Earnings Season?

By Zacks 2022-02-09

Illumina (ILMN) was Upgraded to a Hold Rating at Credit Suisse

By tipranks.com 2022-03-02

$ILMN - Illumina's (ILMN) CEO Francis deSouza on Q4 2021 Results - Earnings Call Transcript.…

By Seekingalpha 2022-02-10

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)